Cytori Therapeutics Inc. (CYTX) Stock Price Down 2.4%
Shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) were down 2.4% on Wednesday . The stock traded as low as $2.03 and last traded at $2.05, with a volume of 61,748 shares changing hands. The stock had previously closed at $2.10.
Several analysts recently weighed in on CYTX shares. Roth Capital started coverage on Cytori Therapeutics in a research note on Monday, March 28th. They set a “buy” rating and a $22.50 target price for the company. Maxim Group restated a “buy” rating and set a $75.00 target price on shares of Cytori Therapeutics in a research note on Thursday, March 24th. Finally, Zacks Investment Research upgraded Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research note on Tuesday, July 12th.
The stock’s market capitalization is $27.60 million. The company has a 50 day moving average price of $2.16 and a 200 day moving average price of $2.86.
Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Tuesday, May 10th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.38. The business earned $2.90 million during the quarter, compared to analysts’ expectations of $2.05 million. Cytori Therapeutics’s revenue was up 26.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.07) EPS. Analysts expect that Cytori Therapeutics Inc. will post ($1.59) earnings per share for the current fiscal year.
Cytori Therapeutics, Inc (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.